Jakarta Post

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post
The Jakarta Post
Video Weather icon 26°C
DKI Jakarta, Indonesia
26°C Light Rain

Rain until tomorrow morning, starting again tomorrow afternoon.

  • Thu

    26℃ - 31℃

  • Fri

    26℃ - 32℃

  • Sat

    27℃ - 32℃

  • Sun

    26℃ - 30℃

Philippines suspends world-first public dengue vaccination program

  •  

    Agence France-Presse

Manila, Philippines | Sun, December 3, 2017 | 06:43 pm
Philippines suspends world-first public dengue vaccination program This file photo taken on April 4, 2016 shows a nurse showing vials of the anti-dengue vaccine Dengvaxia, developed by French medical giant Sanofi, during a vaccination program at an elementary school in suburban Manila. The Philippines said on December 1, 2017 it had suspended use of the landmark vaccine for the potentially deadly dengue virus after its manufacturer warned it could worsen the disease in some cases. The Philippines has vaccinated more than 700,000 children with the drug since 2016 when it became the first country to start using it on a mass scale. (Agence France -Presse/Noel Celis)

The Philippines said Friday it had suspended a landmark public vaccination program for the potentially deadly dengue virus after its manufacturer warned it could worsen the disease in some cases.

French pharmaceutical giant Sanofi announced Wednesday that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.

The Philippines has vaccinated more than 733,000 children with Dengvaxia since 2016 when it became the first country to start using it on a mass scale.

But it said Friday the programme had been suspended.

"In the light of this new analysis, the DOH (Department of Health) will place the dengue vaccination programme on hold while review and consultation is ongoing with experts, key stakeholders, and the WHO (World Health Organization)," Health Secretary Francisco Duque said.

Sanofi had initially said its Dengvaxia vaccine was "critical" in the fight against dengue, the world's most common mosquito-borne virus.

It said Wednesday that a new study has confirmed Dengvaxia's benefits for "those who had prior infection".

"For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection," Sanofi said. 

Duque stressed that the government had not yet received reports of any problems with Dengvaxia.

"Currently, there is no reported case of severe dengue infection among those who received the vaccine," he told reporters.

NEWS PULSE

Join the discussions